A deadly protein is thwarted by the binding of an engineered antibody (gray) to integrin ανβ8 (binding site in red) in this computer model.
Credit: Sci. Transl. Med.
A new study reveals the key role a protein plays in chronic obstructive pulmonary disease (COPD) and provides a potential lead for treating the incurable lung disease (Sci. Transl. Med. 2014, DOI: 10.1126/scitranslmed.3008074).
[+]Enlarge
![]()
A deadly protein is thwarted by the binding of an engineered antibody (gray) to integrin ανβ8 (binding site in red) in this computer model.
Credit: Sci. Transl. Med.
A deadly protein is thwarted by the binding of an engineered antibody (gray) to integrin ανβ8 (binding site in red) in this computer model.
Credit: Sci. Transl. Med.
Stephen L. Nishimura, a professor in the pathology department at the University of California, San Francisco, and colleagues have engineered a monoclonal antibody that prevents the activation of a destructive protein in COPD mouse models and have explored in detail how the antibody binds to its target.
